Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

eFFECTOR Therapeutics, Inc. - Common Stock (NQ:EFTR)

0.1800 UNCHANGED
Last Price Updated: 4:00 PM EDT, Jul 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about eFFECTOR Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Wag! Group Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
S&P 500 Down 2%; Mobilicom Shares Spike Higher
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping more than 2% on Tuesday. The Dow traded down 2.06% to 33,129.04 while the NASDAQ fell 2.39% to 11,506.10. The S&P... 
Via Benzinga
Looking Into eFFECTOR Therapeutics's Return On Capital Employed
Via Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
Dow Tumbles More Than 500 Points; US Manufacturing PMI Rises In February
U.S. stocks traded lower midway through trading, with the Dow Jones dropping more than 500 points on Tuesday. The Dow traded down 1.61% to 33,280.92 while the NASDAQ fell 2.05% to 11,545.79. The S&P... 
Via Benzinga
eFFECTOR Therapeutics Shares Fall After Data From COVID-19 Treatment Trial
Via Benzinga
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
Results presented at 30th Conference on Retroviruses and Opportunistic Infections (CROI) 
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
eFFECTOR Therapeutics to Present at 2023 BIO CEO & Investor Conference
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Why Graphite Bio Shares Are Trading Lower By 50%; Here Are 20 Stocks Moving Premarket
Gainers OncoCyte Corporation (NASDAQ: OCX) rose 89.2% to $0.70 in pre-market trading. Oncocyte, last month, announced an over 40% reduction of its workforce to realign the team towards key products... 
Via Benzinga
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
eFFECTOR Therapeutics Shares Jump After Clinical Update Of Investigational Cancer Drug
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
eFFECTOR Therapeutics Provides Positive Clinical Data Update for Zotatifin and General Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
5 Value Stocks To Watch In The Healthcare Sector
Via Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 79 companies reached new 52-week lows. 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
eFFECTOR Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
eFFECTOR Therapeutics Completes Enrollment in Second of Three Cohorts of Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID-19
Topline data, including safety and viral load reduction results from all three cohorts anticipated in the first half of 2023 
From eFFECTOR Therapeutics, Inc.
Via GlobeNewswire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Good morning, investor! It's time for a breakdown of the biggest pre-market stock movers traders need to know about for Tuesday! 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.